Agreement of efficacy assessments for five‐grass pollen sublingual tablet immunotherapy
Authors:
Abstract
Background: The optimal dose of five‐grass pollen sublingual tablet immunotherapy (SLIT) was established recently by the primary criteria Rhinoconjunctivitis Total Symptom Score (RTSS) from the first treatment season. Secondary and exploratory criteria, such as RTSS at peak pollen season, exploratory combined symptom and rescue medication use score, quality of life and immunological markers are calculated and described in this analysis.Methods: Six hundred and twenty‐eight patients with grass pollen rhinoconjunctivitis (≥2 years duration) were randomized in a double‐blind, placebo‐controlled trial conducted in Europe. Patients received once‐daily SLIT (Stallergenes, Antony, France) of 100IR, 300IR, 500IR or placebo, starting 4 months before grass pollen season and throughout the 2005 season. Patients were instructed to take rescue medication only if symptoms were severe and record symptom severity on using the RTSS.Results: Both 300IR and 500IR doses significantly reduced mean RTSS at pollen peak (P = 0.0005 and P = 0.0014, respectively) and the exploratory combined score (P = 0.0001 and P = 0.0026, respectively) compared with placebo. Compared with patients in the placebo group, those who were taking the 300IR and 500IR doses reported significantly improved quality of life using the mean Rhinoconjunctivitis Quality of Life Questionnaire scores during the peak of the pollen season (P < 0.0001) and at the end of the pollen season (P = 0.0031 and P ≤ 0.0001, respectively). Specific immunoglobulin G4 increased significantly depending on the SLIT dose (P < 0.0001).Conclusions: All secondary efficacy criteria, including efficacy at pollen peak, combined score, quality of life and immunological changes, indicate that 300IR tablets represent the optimal dose and suggest it is appropriate for use in clinical practice.Keywords
This publication has 15 references indexed in Scilit:
- Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5–grass pollen tablet for seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2007
- Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trialsAllergy, 2007
- Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockageAllergy, 2007
- Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapyJournal of Allergy and Clinical Immunology, 2007
- Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforceAllergy, 2007
- Sublingual immunotherapy: efficacy – methodology and outcome of clinical trialsAllergy, 2006
- Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitisAllergy, 2006
- Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis*Allergy, 2004
- Prevalence and rate of diagnosis of allergic rhinitis in EuropeEuropean Respiratory Journal, 2004
- Immunotherapy as an effective tool in allergy treatmentAllergy, 1998